Korea National OncoVenture (NOV) is Korea’s Ministry of Health and Welfare funded oncology drug development program to nurture oncology innovation in the country. To maintain high access and limit costs of oncology therapies, we still need to assist in the development of local Korean biotech companies. — Young-Whan Park, President of National…
Korea Seung-Kyou Lee, vice-president of Korea Bio gives his assessment on the current landscape for biotech firms in Korea. He also discusses Korea Bio’s programme to create a further 1000 biotech firms in Korea within three years. We are at a critical juncture. If we fail to catch up with…
Korea Young-Whan Park, president of National OncoVenture, discusses their programme to support oncology drug development in South Korea, with a view to discovering and producing a globally competitive, Korean-made oncology medicine. Dr Park also provides his assessment of Korea’s challenge in commercialising its academic research. NOV not only supports research…
Korea Christoph Heider, president of the European Chamber of Commerce in Korea (ECCK), discusses the organization, the need for the modernization of the Europe-South Korea Free Trade Agreement, and the future trading relationship between the two economic powerhouses. Multinational pharmaceutical corporations demand more patient access and the abolition of the…
South Korea Southeast Asia’s notoriously strict anti-cannabis laws could be set to relax dramatically as South Korea becomes the first country in the region to legalise cannabis for medicinal use. This surprising move towards legalisation is intended to expand treatment options for patients suffering from rare diseases such as epilepsy. …
Korea Sunyoung Kim, CEO and founder of ViroMed, reveals his strategy for conquering the US market and the feasibility of his ambitions for ViroMed to become the biotech company with the largest revenues from gene therapy by 2025. He also discusses the areas within the Korean biotech sphere that must develop…
Korea In an exclusive interview, Tae-Han Kim, president and CEO of Samsung Biologics, documents his strategy for expanding Samsung’s operations into biologics, and how Samsung Biologics has rapidly become one of the leading Contract Development Manufacturing Organisations (CDMO) in the market in only seven years. Dr Kim also provides his assessment…
Korea Professor Dukgeun Ahn of Seoul National University, trade policy advisor to the Ministry of Health offers his insights into the current policies towards the healthcare industry in Korea, and the potential implications for the US-Korea FTA renegotiations. The rate [of ageing] in Korea is actually even more serious than…
South Korea South Korea’s proposed Moon Jae-In Care has been subject to both praise and protest this year. President Moon Jae-in’s plan dubbed “Moon Care” will be implemented in stages throughout 2022 and pledges to expand healthcare coverage to cover 70 percent of the people’s costs. Korea currently runs on a health…
Korea Jongmoon Kim, CEO of ToolGen discusses the potential for their CRISPR technology to revolutionize not only therapy for genetic illnesses, but also agriculture. Kim explains his move from information technology to biotechnology and the importance of building international partnerships across the industry. CRISPR simplifies some of the complex tasks…
Korea JungTae Park, senior managing director of KoBIA (Korea Biomedicine Industry Association), describes the achievements of the association as a bridge between industry and government. He also highlights the potential of the Korean biopharmaceutical industry to become a global leader in the field. Our priority is to support the globalization…
Korea Jia Liu, CEO of DreamCIS, a Korean CRO, part of the Chinese company Tigermed, talks about her vision for DreamCIS to be “the CRO everybody wants to work with”. Liu assesses the changing environment for clinical research in Korea and offers her view on the successes and scope for improvement…
See our Cookie Privacy Policy Here